Lexicon Pharmaceuticals’ (LXRX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Wednesday,Benzinga reports.

Other equities analysts also recently issued research reports about the stock. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.00.

Lexicon Pharmaceuticals Price Performance

LXRX opened at $0.76 on Wednesday. The company has a market capitalization of $186.20 million, a P/E ratio of -1.01 and a beta of 1.06. The company has a 50-day moving average of $0.79 and a 200-day moving average of $1.37. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals has a 1-year low of $0.62 and a 1-year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. During the same period in the prior year, the firm earned ($0.21) earnings per share. Equities analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after purchasing an additional 11,179,919 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after buying an additional 3,536,805 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Lexicon Pharmaceuticals by 8.4% during the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock worth $5,534,000 after buying an additional 273,436 shares during the period. State Street Corp grew its holdings in Lexicon Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock worth $3,880,000 after buying an additional 157,738 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its holdings in Lexicon Pharmaceuticals by 0.9% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,730,821 shares of the biopharmaceutical company’s stock worth $2,648,000 after buying an additional 14,990 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.